AGN - Allergan plc

NYSE - NYSE Delayed Price. Currency in USD
154.98
+0.77 (+0.50%)
At close: 4:01PM EDT

154.60 -0.38 (-0.25%)
Pre-Market: 7:00AM EDT

Stock chart is not supported by your current browser
Previous Close154.21
Open154.39
Bid153.95 x 900
Ask155.00 x 1400
Day's Range154.02 - 155.99
52 Week Range142.81 - 256.80
Volume1,788,147
Avg. Volume3,157,298
Market Cap52.548B
Beta1.23
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.88 (1.73%)
Ex-Dividend Date2018-02-27
1y Target EstN/A
Trade prices are not sourced from all markets
  • Allergan plc (NYSE:AGN): Has Recent Earnings Growth Beaten Long-Term Trend?
    Simply Wall St.14 hours ago

    Allergan plc (NYSE:AGN): Has Recent Earnings Growth Beaten Long-Term Trend?

    After reading Allergan plc’s (NYSE:AGN) most recent earnings announcement (31 March 2018), I found it useful to look back at how the company has performed in the past and compareRead More...

  • Fifth Third Bancorp and Celgene: Top Losses on May 21
    Market Realist23 hours ago

    Fifth Third Bancorp and Celgene: Top Losses on May 21

    The S&P 500’s top losses on May 21 were: Fifth Third Bancorp (FITB) declined 7.9%. Celgene (CELG) declined 4.7%. Symantec (SYMC) declined 2.7%. Allergan (AGN) declined 2.7%. Campbell Soup (CPB) declined 2.3%. Fifth Third Bancorp

  • Benzingayesterday

    Jim Cramer Weighs In On Royal Caribbean Cruises, Allergan And More

    Jim Cramer said on CNBC's "Mad Money Lightning Round" that Royal Caribbean Cruises Ltd (NYSE: RCL ) is a buy. People are worried about raw costs and too many ships, but they're wrong, said Cramer. ...

  • CNBCyesterday

    Cramer's lightning round: The bears are wrong about cruise ship stocks

    It's that time again! "Mad Money" host Jim Cramer rang the lightning round bell, which means he gave his take on callers' favorite stocks at rapid speed. Royal Caribbean RCL : "People are too worried about raw costs. Tyson Foods, Inc. TSN : "I think the stock's come down a lot, but I have no catalysts and people did not like that last quarter, to be candid.

  • Associated Press2 days ago

    Business Highlights

    A divided Supreme Court has ruled that businesses can prohibit their workers from banding together in disputes over pay and conditions in the workplace, a decision that affects an estimated 25 million non-unionized employees. In exchange for the United States agreeing to hold off on tariffs on Chinese products, Beijing agreed over the weekend to "substantially reduce" America's huge trade deficit with China. DETROIT (AP) -- Long emergency stopping distances, difficult-to-use controls and a harsh ride stopped Tesla's Model 3 mass-market electric car from getting a recommended buy rating from Consumer Reports.

  • Associated Press2 days ago

    Dispute on eye drop size fails to catch Supreme Court's eye

    WASHINGTON (AP) — A dispute about the size of eye drops has failed to catch the eye of the Supreme Court.

  • Top Research Reports for Walmart, AT&T & Novo Nordisk
    Zacks5 days ago

    Top Research Reports for Walmart, AT&T & Novo Nordisk

    Top Research Reports for Walmart, AT&T & Novo Nordisk

  • David Tepper gets US approval to take activist stance on Allergan, if he wants it
    CNBC5 days ago

    David Tepper gets US approval to take activist stance on Allergan, if he wants it

    FTC approval gives Tepper's Appaloosa Management flexibility if it decides it wants to be more than a passive investor.

  • TheStreet.com5 days ago

    Facebook Directors Face New Challenges; Allergan Talks Botox Competitors--ICYMI

    Markets turned to the red on Thursday amid the last big push of earnings for the second quarter, and while global energy markets remained hot as oil prices continue to rise, for better or worse. proved many investors wrong after its first quarter earnings, but as its annual meeting approaches the company is again feeling the heat. The two major investor advisory firms this week urged Facebook shareholders to vote against several of the company's directors at its May 31 annual meeting.

  • Appaloosa gets permission for activist stance with Allergan stake
    Reuters6 days ago

    Appaloosa gets permission for activist stance with Allergan stake

    David Tepper's Appaloosa Management and two of his funds received Federal Trade Commission clearance earlier this week that could clear the way for the billionaire to become an activist investor in drugmaker Allergan Plc. Tepper received the Hart-Scott-Rodino anti-trust clearances on Wednesday, according to the FTC's website. Wells Fargo analyst David Maris said in a research note that Allergan "indicated this clearance provides flexibility to the filer as to whether they want take an activist approach to the investment or not." Tepper's Appaloosa LP increased its stake in Allergan to 3.7 million shares from around 3.5 million shares over the last quarter, the firm said in a filing with the Securities and Exchange Commission on Tuesday.

  • Appaloosa gets permission for activist stance with Allergan stake
    Reuters6 days ago

    Appaloosa gets permission for activist stance with Allergan stake

    David Tepper's Appaloosa Management and two of his funds received Federal Trade Commission clearance earlier this week that could clear the way for the billionaire to become an activist investor in drugmaker Allergan Plc. Tepper received the Hart-Scott-Rodino anti-trust clearances on Wednesday, according to the FTC's website. Tepper's Appaloosa LP increased its stake in Allergan to 3.7 million shares from around 3.5 million shares over the last quarter, the firm said in a filing with the Securities and Exchange Commission on Tuesday.

  • TheStreet.com6 days ago

    Allergan's Meury Talks Market Expansion in Aesthetics

    Botox faces a delay in getting to market, Allergan is anything but frozen. "Of course, it's always interesting when a company takes more time to get to market," Allergan chief commercial officer William Meury said at the Bank of America healthcare conference in Las Vegas on Thursday, May 17. Meury's appearance at the conference came a day after competitor Evolus Inc.

  • Walmart under pressure, Allergan's up, Alphabet dips
    Yahoo Finance6 days ago

    Walmart under pressure, Allergan's up, Alphabet dips

    Walmart, Allergan and Alphabet are the Yahoo Finance charts of the day.

  • Walgreen, Kroger, Albertsons, HEB sue Allergan over dry-eye drug
    Reuters7 days ago

    Walgreen, Kroger, Albertsons, HEB sue Allergan over dry-eye drug

    By Jonathan Stempel NEW YORK (Reuters) - Allergan Inc was sued on Wednesday by four large U.S. retailers that accused the drugmaker of antitrust violations for trying to stop rivals from selling generic versions of Restasis, its medication to treat dry-eye disease. Walgreen Co, Kroger Co, Albertsons Cos and HEB Grocery Co accused Allergan of illegally preserving its monopoly by obtaining illegal patents, suing rivals that challenged those patents and transferring the patents to a sovereign Native American tribe, New York's Saint Regis Mohawk Tribe, to escape scrutiny by U.S. courts.

  • Walgreen, Kroger, Albertsons, HEB sue Allergan over dry-eye drug
    Reuters7 days ago

    Walgreen, Kroger, Albertsons, HEB sue Allergan over dry-eye drug

    Allergan Inc was sued on Wednesday by four large U.S. retailers that accused the drugmaker of antitrust violations for trying to stop rivals from selling generic versions of Restasis, its medication to treat dry-eye disease. Walgreen Co, Kroger Co, Albertsons Cos and HEB Grocery Co accused Allergan of illegally preserving its monopoly by obtaining illegal patents, suing rivals that challenged those patents and transferring the patents to a sovereign Native American tribe, New York's Saint Regis Mohawk Tribe, to escape scrutiny by U.S. courts.

  • Reuters7 days ago

    Evolus investors frown as FDA declines to approve Botox rival

    U.S. health regulators on Wednesday declined to approve Evolus Inc's rival product to Allergan Plc's Botox, citing deficiencies related to the chemistry and manufacturing of its potential treatment for frown lines sending its shares down as much as 35 percent. The deficiencies that were communicated by the U.S. Food and Drug Administration in a so-called complete response letter were "manageable", according to CEO Moatazedi, who joined the company earlier this month after serving as U.S. head of Allergan's medical aesthetics business.

  • Teva’s Debt Reduction Plans Progress, Targets Are on Track
    Market Realist7 days ago

    Teva’s Debt Reduction Plans Progress, Targets Are on Track

    Teva Pharmaceutical (TEVA) has been working towards paying down the high level of debt on its balance sheet. Teva obtained the debt in 2016 to fund the acquisition of Allergan’s (AGN) generic business. At the end of fiscal 2017, Teva had a net debt of $31.5 billion on its balance sheet.

  • Why Evolus, Inc. Is Crashing Today
    Motley Fool7 days ago

    Why Evolus, Inc. Is Crashing Today

    Shares swoon after the FDA gives the thumbs down to its lead compound. Here's what investors need to know.

  • The Wall Street Journal9 days ago

    [$$] CEO Pay and Performance Often Don't Match Up

    The better the company and its shareholders do, the more the top boss should be paid, or so the pay-for-performance mantra goes. In reality, CEO pay and performance often don’t match up, and 2017 was no exception. Among S&P 500 CEOs who got raises last year, the 10% who received the biggest pay increases scored—as a group—in the middle of the pack in terms of total shareholder return, according to a Wall Street Journal analysis of data from MyLogIQ LLC and Institutional Shareholder Services.

  • 6 Days Left To Allergan plc (NYSE:AGN)’s Ex-Dividend Date, Is It Worth Buying?
    Simply Wall St.13 days ago

    6 Days Left To Allergan plc (NYSE:AGN)’s Ex-Dividend Date, Is It Worth Buying?

    Shares of Allergan plc (NYSE:AGN) will begin trading ex-dividend in 6 days. To qualify for the dividend check of $0.72 per share, investors must have owned the shares prior toRead More...

  • Musk Meltdown Underscores Art of Keeping Earnings Calls Dull
    Bloomberg14 days ago

    Musk Meltdown Underscores Art of Keeping Earnings Calls Dull

    From the tedious disclaimers at the outset about “forward-looking statements,” to the desiccated remarks read by leaden financial officers, to the mealy mouthed questions posed by unctuous analysts, the calls tend to emit a tonal range so monotonous that you can listen to hundreds of the proceedings without hearing a single memorable thing. Elon Musk’s recent unruly performance during Tesla’s earnings call -- where he bizarrely chastised analysts, telling them among things that “boring, bonehead questions are not cool” -- was a reminder of just how seldomly these rituals of corporate pageantry go off the rails. “You never want to see your management representatives fly off the handle with investors,” said Christopher King, vice president of investor relations at Windstream Holdings Inc., which provides telecom services in rural areas.

  • Bloomberg14 days ago

    How Companies Keep Most Earnings Calls So Incredibly Boring

    From the tedious disclaimers at the outset about “forward-looking statements,” to the desiccated remarks read by leaden financial officers, to the mealy mouthed questions posed by unctuous analysts, the calls tend to emit a tonal range so monotonous that you can listen to hundreds of the proceedings without hearing a single memorable thing. Elon Musk’s recent unruly performance during Tesla’s earnings call -- where he bizarrely chastised analysts, telling them among things that “boring, bonehead questions are not cool” -- was a reminder of just how seldomly these rituals of corporate pageantry go off the rails.

  • Walmart, Allergan and Alphabet are the Yahoo Finance charts of the day.
    Yahoo Finance Video6 days ago

    Walmart, Allergan and Alphabet are the Yahoo Finance charts of the day.

    Let's check out the Yahoo Finance charts of the day. Walmart (WMT): Shares are down in early trade,  around 2%. The retail chain reported fiscal first-quarter earnings that beat expectations on the top and bottom lines, as its e-commerce business rebounded. Allergan (AGN): Shares are up here, around 1%. The global pharmaceutical company was sued by four large U.S. retailers that accused the drugmaker of antitrust violations for trying to stop rivals from selling generic versions of Restasis, its medication to treat dry-eye disease. Alphabet (GOOG): Shares are down here,  around .32%.  Alphabet's YouTube said it will launch a new music streaming service, YouTube Music, next week and unveil soon a premium service that will charge more for its original shows. For more on today's big stock movers check out the Final Round, live at 3:55 p.m. ET, right here on Yahoo Finance.

  • Big Pay, Little Return
    Yahoo Finance Video9 days ago

    Big Pay, Little Return

    Top CEOs get paid millions, but new study shows that does not always lead to a good return for investors. Yahoo Finance's Seana Smith, Andy Serwer and Julia La Roche discuss.

  • MARKETS: Biotech and pharma stocks could be the key to the market bull case
    Yahoo Finance Video13 days ago

    MARKETS: Biotech and pharma stocks could be the key to the market bull case

    Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.